Dr. Cotter explains how utilizing clinical trial data can help clinicians overcome therapeutic inertia regarding the use of JAK inhibitors for patients with atopic dermatitis based on a presentation at DEF Essential Resource Meeting 2026 (DERM2026) NP/PA CME Conference. He highlights upadacitinib as a highly effective average medication for patients aged 12 or older with moderate-to-severe atopic dermatitis. He addresses safety concerns by explaining that the drug’s box warning is a class-wide designation stemming from a different medication rather than elevated incident rates in upadacitinib cohorts. Ultimately, he noted that understanding this data helps clinicians guide patients toward appropriate choices without letting safety misunderstandings prevent necessary treatment.
